產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-SPATA12抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-SPATA12抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-SPATA12
Cat. Number:
Anti-SPATA12抗體KL-1898R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
SPATA12, also known as SRG5 (Spermatogenesis-related protein 5), is a 190 amino acid protein that may be involved in theAnti-SPATA12抗體 regulation of spermatogenesis. SPATA12 is expressed in normal ***** testis, but is absent in fetal testis, implying that it may be involved in the development of testicular maturation. Specifically, SPATA12 is expressed in spermatocytes, spermatids and spermatozoa, with no expression in Leydig and Sertoli cells. Studies with HeLa and GC-1 germ cells indicate that expression of the SPATA12 gene may delay the progression of G1 to S in the cell cycle, therefore it is thought that SPATA12 maintains the cell in a differentiated state and suppresses cell proliferation.
Also known as:
Spermatogenesis-associated protein 12; Spermatogenesis associated 12; Spermatogenesis-related protein 5; SPT12_HUMAN; Anti-SPATA12抗體SPATA12; SRG5; Testis Spermatogenesis Related Gene5.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, .
●
Immunogen: KLH conjugated Anti-SPATA12抗體synthetic peptide derived from human SPATA12.
●
Predicted Molecular Weight: 20kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:50-200 IF=1:100-500 Anti-SPATA12抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
